Latest From Alcon Inc.
The Basel-headquartered company has launched three high-profile drugs in the past couple of months. Analysts are waiting to see what initial impact these potential future growth drivers are having.
Following first anniversary of Lumify launch, "we're still in a pretty heavy investment period supporting trial because our data suggest that when people use the product, they persist in using the product. And so for now, we got our foot down on of the promotional side," says CFO Paul Herendeen.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Alcon Inc.
- Senior Management
David Endicott, CEO
Timothy C Stonesifer, SVP, CFO
Franck Leveiller, SVP, Head, Global R&D
Laurent Attias, Head, Global Corp. Dev. Strategy, BD&L, & M&A
Ed McGough, SVP, Global Mfctng. & Technical Operations
- Contact Info
Avenue Louis-Casaï 58
Cointrin-Geneva, TX CH-1216
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.